Research programme: carbon nanotube anticancer therapeutics - Ensysce Biosciences
Latest Information Update: 11 Jul 2015
At a glance
- Originator Ensysce Biosciences
- Class Doxorubicins; Paclitaxels; Small interfering RNA
- Mechanism of Action DNA intercalators; Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; RNA interference; Tubulin inhibitors; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer